[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].
- DOI
- 10.3760/cma.j.cn112152-20250619-00280
- Published
- 2026-04-01
- Container
- Zhonghua Zhong Liu Za Zhi
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3760/cma.j.cn112152-20250619-00280,
title = {[Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].},
author = {Jia YF and Xia J and Liu XM and Li ZH and Man L and Zhou CY and Cui XJ and Chen MB and Wang YB and Wang S and Sun T.},
year = {2026},
journal = {Zhonghua Zhong Liu Za Zhi},
doi = {10.3760/cma.j.cn112152-20250619-00280},
url = {https://doi.org/10.3760/cma.j.cn112152-20250619-00280}
}RIS
TY - JOUR TI - [Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial]. AU - Jia YF AU - Xia J AU - Liu XM AU - Li ZH AU - Man L AU - Zhou CY AU - Cui XJ AU - Chen MB AU - Wang YB AU - Wang S AU - Sun T. PY - 2026 JO - Zhonghua Zhong Liu Za Zhi DO - 10.3760/cma.j.cn112152-20250619-00280 UR - https://doi.org/10.3760/cma.j.cn112152-20250619-00280 ER -
APA
YF, J., J, X., XM, L., ZH, L., L, M., CY, Z., XJ, C., MB, C., YB, W., S, W., & T., S. (2026). [Comparison of the efficacy and safety of 36 000 IU vs. 40 000 IU recombinant human erythropoietin for the treatment of cancer-related anemia: a multicenter, open-label, randomized controlled trial].. Zhonghua Zhong Liu Za Zhi. https://doi.org/10.3760/cma.j.cn112152-20250619-00280
Source records
- europe-pmc · retrieved 2026-09-27T05:11:27.881Z